GLP-1 timing and pregnancy blood pressure

A systematic review and meta-analysis published in Endocrine on 31 July 2026 pooled three retrospective cohort studies covering 10,880 pregnancies and found no statistically significant association between GLP-1 receptor agonist exposure around conception and hypertensive disorders of pregnancy. The pooled odds ratio was 0.91, with a 95% confidence interval running from 0.57 to 1.47^[1]. That is a null result on a small evidence base, and it is not a signal that these drugs are cleared for use in pregnancy. The UK and EU product information for tirzepatide still states that it should not be used during pregnancy^[3], and nothing in this paper changes that.

What the review actually pooled

The authors searched PubMed, Scopus, EMBASE, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov through 15 December 2025, and restricted inclusion to observational cohort studies reporting hypertensive disorder outcomes. Case reports and reviews without such data were excluded. Three retrospective cohorts met the criteria, all of them US-based and covering 2014 to 2025. Together they contributed 4,942 pregnancies exposed to a GLP-1 receptor agonist and 5,938 unexposed pregnancies. The pooling used a random-effects Mantel-Haenszel model, and risk of bias was assessed with the ROBINS-I tool^[1].

Seven drugs appear across the exposed group: semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide, lixisenatide and albiglutide^[1]. The exposure window is periconceptional or first-trimester use, so the women in these cohorts were mostly on the drug around the time they conceived rather than throughout pregnancy. The authors' conclusion is narrow and matches the number: that exposure was not significantly associated with hypertensive disorder risk, and the evidence base is too limited to be definitive without larger prospective studies^[1].

The labels have not moved

The regulatory position is unchanged and worth stating plainly. The US Mounjaro prescribing information lists only two contraindications, a personal or family history of medullary thyroid carcinoma or MEN 2, and serious hypersensitivity to the drug. Pregnancy is handled in section 8.1 instead, which says available data in pregnant women are insufficient to evaluate a drug-related risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes, and that animal reproduction studies point to possible fetal risk. In pregnant rats and rabbits dosed during organogenesis, the label reports fetal growth reductions and fetal abnormalities at clinically relevant exposures^[2].

The European and UK summary of product characteristics goes further. It says tirzepatide should not be used during pregnancy, advises women of childbearing potential to use contraception during treatment, and instructs anyone planning a pregnancy to stop at least one month beforehand because of the drug's long half-life^[3]. Mounjaro is centrally authorised across the EU for type-2 diabetes and weight management, and is prescription-only everywhere it is sold^[4]. One practical detail readers miss: the US label tells patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting the drug and after each dose increase, because slowed gastric emptying can blunt absorption^[2].

Why three studies cannot settle this

Look at the confidence interval rather than the point estimate. An interval spanning 0.57 to 1.47 is consistent with a meaningful reduction in risk, with no effect at all, and with a moderate increase in risk^[1]. A null result of that width is a statement about how little data exists, not a demonstration of safety. Three retrospective cohorts drawn entirely from US records is a thin base for a question this consequential.

There is a harder problem underneath. Women prescribed these drugs have obesity or type-2 diabetes, and both are themselves risk factors for hypertensive disorders of pregnancy. CDC surveillance recorded hypertensive disorders in 13.3% of US delivery hospitalisations in 2017 and 15.9% in 2019, and attributed part of that rise to increasing prevalence of risk factors including advanced maternal age, obesity and diabetes^[5]. Comparing exposed and unexposed pregnancies in retrospective records means comparing two groups that differ in ways that push the result in opposite directions. The exposed group starts at higher baseline risk, but may also have lost weight and improved glycaemic control before conceiving. Separating those effects needs designs these three cohorts do not have.

What this paper does not answer

The published abstract reports one pooled figure for hypertensive disorders of pregnancy as a category. It does not separate preeclampsia from gestational hypertension, and it does not compare exposure timing strata against each other despite timing appearing in the title. So it cannot tell us whether stopping three months before conception differs from stopping at a positive test. It also pools seven drugs with different half-lives and receptor targets, so no tirzepatide-specific or semaglutide-specific estimate can be read out of it. And it says nothing about continued use through pregnancy, because almost nobody in these cohorts did that.

This also sits alongside, not on top of, the fetal-outcome question, which we cover separately in our piece on semaglutide in pregnancy, and the conception question covered in our write-up of the weight-lowering drugs and female fertility meta-analysis. Maternal blood pressure, fetal development and time to conception are three different outcomes with three different evidence bases, and a reassuring number in one does not carry over to the others.

Where this lands

If you are pregnant, trying to conceive, or using a GLP-1 receptor agonist and unsure about timing, this is a conversation for a clinician who knows your history and can weigh your own baseline risk. It is not a decision to make from a meta-analysis abstract, a forum thread or a vendor page, and PeptideMethods cannot advise on it. What we can say is what the evidence currently supports: one small pooled analysis found no significant link between periconceptional GLP-1 exposure and hypertensive disorders of pregnancy, the authors themselves call the evidence limited^[1], and the labels still tell people to be off these drugs before and during pregnancy^[3]. For how tirzepatide and semaglutide are regulated where you live, see the tirzepatide regulation pages.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.